



- (51) International Patent Classification:
C40B 40/06 (2006.01) *C12Q 1/68* (2006.01)
C12N 15/12 (2006.01) *G01N 33/50* (2006.01)
- (21) International Application Number:
PCT/US2012/041379
- (22) International Filing Date:
7 June 2012 (07.06.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/494,773 8 June 2011 (08.06.2011) US
- (71) Applicant (for all designated States except US): **DEN-
OVO BIOMARKERS INC.** [US/US]; 5003 Ruelle De
Mer, San Diego, CA 92130 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **LOU, Wen** [US/US];
5003 Ruelle De Mer, San Diego, CA 92130 (US).
- (74) Agents: **CHEN, Peng** et al.; MORRISON & FOERSTER
LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA
92130-2040 (US).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS OF PREDICTING ACTIVITY OF RETINOID X RECEPTOR MODULATOR




FIG. 4

(57) Abstract: The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*